An AI-enhanced knowledge base integrates machine learning and natural language processing to organize, interpret, and surface relevant insights from vast scientific datasets.

Accelerated approval is a regulatory pathway that allows earlier market access for therapies that address serious conditions and fill an unmet medical need based on surrogate endpoints.

The addressable population is the subset of patients within a broader disease area who meet specific criteria for treatment with a given product or intervention.

An advisory board is a structured meeting where external experts provide insights to support strategic, clinical, or scientific decision-making in pharmaceutical development.

Artificial intelligence (AI) refers to computer systems designed to perform tasks that typically require human intelligence, such as learning, reasoning, and decision-making.

An asset evaluation establishes the attractiveness, market potential and likelihood of success for an internal or external asset.

Attribution refers to the process of linking a scientific, clinical, or strategic outcome to a specific source, action, or stakeholder, ensuring transparency and traceability.

Benefit-risk assessment is the structured evaluation of a treatment’s positive therapeutic effects against its potential risks, informing regulatory and clinical decisions.

Bibliometric analysis is the application of statistical methods to the study of publication data.

Bibliometrics refers to the quantitative analysis of academic publications used to evaluate research performance and influence.

A biosimilar is a biologic medicine that is highly similar to an already approved reference biologic, with no clinically meaningful differences in safety, purity, or efficacy.

In market access and regulatory contexts, burden of proof refers to the obligation of pharmaceutical companies to demonstrate the value, efficacy, and safety of their products to key stakeholders.

Channel strategy refers to how pharmaceutical companies engage different communication and access pathways to reach key stakeholders across medical, payer, and patient channels.

Clinical benefit refers to the positive impact a treatment has on patient health, including symptom relief, disease modification, or survival improvement.

Clinical development is the systematic process of testing a new medical intervention in humans to establish its safety and efficacy.

Clinical differentiation is the degree to which a product stands out from alternatives based on its therapeutic profile, safety, or ease of use.

The clinical landscape refers to the current state of clinical development activity within a specific disease area, including ongoing and completed trials, treatment approaches, and emerging standards of care.

Clinical landscaping is a comprehensive assessment that provides a holistic view of a particular therapeutic area.

Clinical meaningfulness describes the real-world relevance of a treatment’s effects on outcomes that matter to patients, providers, and payers.

Co-author impact factor is a derived metric that assesses the influence of an author’s collaborators based on their publication activity and citation history.

A collaboration network is a visual or analytical representation of co-authorship and institutional relationships within scientific research communities.

Comparative effectiveness evaluates how a treatment performs relative to other available options in terms of efficacy, safety, and real-world outcomes.

The competitive landscape refers to the current set of products, companies, and strategies competing within a specific therapeutic area, market, or indication.

Competitive landscaping is the analysis of current and future market competitors to inform strategic business decisions.

The conference landscape refers to the network of scientific and medical meetings where new clinical data, research, and strategic priorities are presented and discussed.

Conference landscaping is the systematic analysis of relevant scientific and medical meetings to identify key themes, trends, stakeholders, and strategic opportunities.

Conference planning is the strategic coordination of a pharmaceutical company’s activities before, during, and after a scientific or medical meeting to maximize scientific impact and stakeholder engagement.

At VISFO, a Digital Opinion Leader (DOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank DOLs.

A decentralized clinical trial (DCT) is a study that uses digital tools and remote methods to reduce or eliminate the need for in-person site visits.

A development pipeline is a set of drug candidates that an individual pharmaceutical company (or the entire industry collectively) has under discovery or development at any given point in time.

A DOL is an influential person or organization with a large online presence, often on social media, in the healthcare or pharmaceutical industry.

Digital activity refers to the online engagement of stakeholders across platforms such as social media, webinars, and digital conferences, providing insights into their interests, influence, and network.

The digital landscape refers to the network of online platforms, behaviors, and content shaping scientific dialogue, stakeholder engagement, and perception within a therapeutic area.

Digital landscaping is the structured analysis of online activity to identify key stakeholders, emerging trends, and scientific conversations within a therapeutic area.

Digital listening is the continuous monitoring and analysis of online conversations to capture insights on stakeholder perspectives, emerging topics, and perceptions of scientific data.

Digital transformation is the integration of digital technologies into core pharmaceutical operations to enhance scientific, clinical, and commercial performance.

Disease burden refers to the total impact of a health condition on individuals, healthcare systems, and society, including clinical, economic, and quality-of-life dimensions.

Disease severity refers to the extent or intensity of a condition’s impact on a patient’s health, functioning, and quality of life.

Dose optimization is the process of identifying the most effective and safe drug dose for a specific patient population.

An early access program (EAP) allows patients with serious or life-threatening conditions to access investigational therapies prior to full regulatory approval.

Economic modeling involves the use of mathematical frameworks to estimate the cost-effectiveness, budget impact, or value of healthcare interventions.

Eligibility criteria are the inclusion and exclusion rules that define which participants can enroll in a clinical trial.

Engagement planning is the strategic design of how and when to interact with external stakeholders to support scientific, clinical, and commercial goals.

Epidemiology is the study of the distribution, patterns and determinants of health across defined populations.

An evidence hierarchy is a ranked framework that classifies types of evidence based on their methodological rigor and reliability.

An evidence-generation program is a coordinated plan for producing clinical, real-world, and economic data to support the value and positioning of a pharmaceutical product.

An external control arm uses data from outside a clinical trial to serve as a comparator for evaluating a treatment’s effectiveness.

Feasibility planning is the process of evaluating whether a clinical trial or development strategy can be successfully executed based on operational, scientific, and market factors.

First-author refers to the individual credited with leading the design, execution, and authorship of a scientific publication.

Formulary inclusion is the decision by a healthcare payer or institution to list a pharmaceutical product as an approved treatment option.

Gap analysis is the process of identifying missing evidence, insights, or capabilities needed to meet strategic, regulatory, or stakeholder expectations.

A generic is a medication that is chemically identical to an approved brand-name drug and intended to offer the same clinical benefit at a lower cost.

A global value dossier (GVD) is a comprehensive document that compiles all supporting evidence for a product’s value, designed for use in payer and HTA submissions worldwide.

An HEOR stakeholder is an individual or organization that uses health economics and outcomes research to guide decisions in healthcare policy, reimbursement, or treatment adoption.

An HTA submission is a formal package of clinical and economic evidence provided to a health technology assessment body to support product reimbursement or funding.

HEOR is the discipline focused on evaluating the economic value, clinical outcomes, and humanistic impact of healthcare interventions to inform decision-making.

A health economic model is a structured tool used to estimate the costs and outcomes associated with a healthcare intervention over time.

A health technology assessment (HTA) is a systematic evaluation of the clinical, social, economic and ethical implications of a new medical intervention or technology.

Implementation science is the study of how to promote the adoption and integration of evidence-based practices into real-world healthcare settings.

In epidemiology, incidence is the rate at which new cases of a disease occur in a population over a specific time period.

Inclusion and exclusion criteria define who can or cannot participate in a clinical trial, based on factors like disease state, age, comorbidities, or prior treatment.

Indications are the specific medical conditions or diseases for which a treatment or intervention is approved.

An indication assessment is the strategic evaluation of market opportunities within multiple potential indications to determine which to prioritize for development and launch, and maximize the commercial success of a new product or medical device.

An insight is understanding derived from data or a lived experience that reveals a trend, need, or opportunity.

Institutional affiliation refers to the academic, research, or clinical organization with which a healthcare professional is formally associated.

An integrated evidence plan (IEP) outlines the coordinated generation of clinical, economic, and real-world data to support a product’s lifecycle strategy.

An intelligence board is an expert-curated synthesis of evidence, data, and strategic insights designed to support pharmaceutical decision-making on specific questions or topics.

Internal buy-in refers to gaining cross-functional agreement and support for a strategic decision, investment, or action plan within a pharmaceutical organization.

An investigator-initiated study (IIS) is a clinical or scientific study developed and led by an independent researcher, often supported by pharmaceutical funding or materials.

Journal prestige refers to the perceived authority, influence, and visibility of a scientific journal within its field, beyond its impact factor alone.

At VISFO, a Key Clinical Investigator (KCI) impact factor is a proprietary bibliometric-based calculation used to identify and rank KCIs.

At VISFO, a Key Opinion Leader (KOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank KOLs.

A Key Clinical Investigator (KCI) is a highly experienced healthcare professional with a proven track record in conducting successful clinical trials.

A Key Opinion Leader (KOL) is a highly influential and respected expert in their field who shapes opinions and decisioning.

Key Opinion Leader (KOL) mapping is the process of identifying and analyzing key opinion leaders based on their influence, expertise, and relevance to a specific therapeutic area or strategy.

Launch sequence optimization is a strategic process that determines the best order and timing for launching a new drug across different markets.

Lifecycle evidence generation is the strategic planning and execution of data generation activities throughout a product’s development, launch, and post-market phases.

Line of therapy refers to the sequence in which treatments are given to a patient, typically categorized as first-line, second-line, or third-line based on clinical guidelines or treatment history.

A literature library is a curated collection of publications relevant to a specific individual, topic, or strategy, used to support insight generation and engagement planning.

Market Access is a function within pharmaceutical and biotechnology companies ensuring that the patients most likely to benefit from a new drug can access it, and that the drug is both cost-effective for healthcare systems and commercially viable for the manufacturer.

A Market Access Key Opinion Leader (MAKOL) is a recognized expert who regularly publishes on market access themes, for example, disease burden, treatment cost-effectiveness and reimbursement challenges, within a specific therapeutic area.

Market conditioning is the strategic process of shaping stakeholder awareness, perceptions, and expectations ahead of product launch or clinical milestone.

Market potential is the estimated maximum revenue opportunity for a pharmaceutical product within a defined population, therapeutic area, or geography.

Market shaping is the deliberate effort to redefine or expand a therapeutic space by influencing standards of care, stakeholder behavior, or access pathways.

Market value refers to the current or projected financial worth of a pharmaceutical product or therapeutic area based on real-world sales, pricing, and market dynamics.

Medical Affairs is a strategic function within the pharmaceutical, biotechnology and consumer healthcare industries that communicates scientific data to healthcare professionals, payers and policymakers.

A Medical Science Liaison (MSL) is a scientific expert who engages with healthcare professionals to communicate clinical data and gather insights that inform medical and commercial strategy.

Medical insight capture is the process of collecting, analyzing, and synthesizing insights from healthcare professionals to inform strategy and decision-making.

Medical strategy is the plan that guides how scientific and clinical knowledge is generated, interpreted, and communicated throughout a product’s lifecycle.

Mentions are instances where a specific product, topic, company, or stakeholder is referenced in digital content such as social media posts, articles, webinars, or forums.

Modeling is the process of using mathematical frameworks to simulate clinical, economic, or epidemiological scenarios to support pharmaceutical decision-making.

Morbidity rate is a measure of how frequently a disease or health condition occurs within a specific population over a defined period of time.

Mortality rate is a measure of the frequency of death in a defined population over a specified period, often used to assess the severity or impact of a disease.

Multi-stakeholder engagement refers to the coordinated interaction with diverse healthcare decision-makers, including providers, payers, regulators, and patient advocates.

Multiplicity refers to the increased risk of false-positive results when multiple statistical tests are performed in a clinical trial.

Net clinical benefit refers to the overall advantage of a treatment when weighing its therapeutic effects against its risks in real-world patient care.

An observational study is a non-interventional research design that evaluates outcomes in patients receiving routine medical care.

An outcomes-based agreement links a drug’s reimbursement to the real-world results it delivers in a patient population.

At VISFO, a Payer Influencing Key Opinion Leader (PIKOL) impact factor is a proprietary bibliometric-based calculation used to identify and rank PIKOLs.

A patient advocacy group is an organization that represents the interests of individuals affected by a particular disease or condition, often influencing research, policy, and access.